Fresenius SE KGaAXSWX:FRE 71 Debt-to-EBITDA is 3.41 as of Mar. 2026, which is 7% below its 10-year median of 3.68. GuruFocus rates XSWX:FRE with a GF Score™ of 71/100 and a GF Value™ of CHF33.50 (Fairly Valued). The stock has 5 warning signs investors should review. Among 476 Healthcare Providers & Services companies, Fresenius SE KGaA ranks worse than 63.03% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Fresenius SE KGaA's Debt-to-EBITDA or its related term are showing as below:
XSWX:FRE'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 2.63 Med: 3.68 Max: 8.96
Current: 3.24
During the past 13 years, the highest Debt-to-EBITDA Ratio of Fresenius SE KGaA was 8.96. The lowest was 2.63. And the median was 3.68.
XSWX:FRE's Debt-to-EBITDA is ranked worse than 63.03% of 476
companies
in the Healthcare Providers & Services industry
Industry Median: 2.25
vs XSWX:FRE: 3.24
Fresenius SE KGaA (XSWX:FRE) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Fresenius SE KGaA Debt-to-EBITDA Related Terms
Fresenius SE KGaA Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Fresenius SE KGaA's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:FRE vs HCA, THC, DVA: Debt-to-EBITDA Comparison
For the Medical Care Facilities subindustry, Fresenius SE KGaA's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fresenius SE KGaA Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Fresenius SE KGaA's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Fresenius SE KGaA's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Fresenius SE KGaA (XSWX:FRE) has a Debt-to-EBITDA of 3.41 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Fresenius SE KGaA. This is near median its historical median of 3.68. Over the past decade, Fresenius SE KGaA's Debt-to-EBITDA has ranged from 2.63 to 8.96. According to the industry distribution chart, Fresenius SE KGaA ranks #300 out of 476 companies in the Healthcare Providers & Services industry, placing it in the top 63%.
Is Fresenius SE KGaA's Debt-to-EBITDA too high?
Fresenius SE KGaA's current Debt-to-EBITDA of 3.41 is near median its 10-year median of 3.68. Over the past 10 years, this metric has ranged from a low of 2.63 to a high of 8.96. The Healthcare Providers & Services industry median Debt-to-EBITDA is 2.25. Fresenius SE KGaA's value of 3.41 is 51.6% above this industry median. Based on the distribution chart, Fresenius SE KGaA ranks #300 out of 476 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Fresenius SE KGaA has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fresenius SE KGaA's Debt-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Fresenius SE KGaA ranks #300 out of 476 companies for Debt-to-EBITDA. This places Fresenius SE KGaA in the lower half of its industry. The industry median Debt-to-EBITDA is 2.25. Fresenius SE KGaA's value of 3.41 is 51.6% above this benchmark. Historically, Fresenius SE KGaA's own Debt-to-EBITDA has ranged from 2.63 to 8.96 over the past decade. While the company's 10-year median is 3.68 vs. the industry median of 2.25, Fresenius SE KGaA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.25, based on 476 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fresenius SE KGaA's current Debt-to-EBITDA of 3.41 is 51.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Fresenius SE KGaA. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fresenius SE KGaA's current Debt-to-EBITDA is 3.41, which is near median its own 10-year median of 3.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fresenius SE KGaA stock overvalued right now?
Based on GuruFocus' analysis, Fresenius SE KGaA (XSWX:FRE) is currently considered Fairly Valued. The stock's GF Value™ is CHF33.50, compared to a current price of CHF36.15 — trading 7.9% above its estimated fair value. The current Debt-to-EBITDA is 3.41, which is near median its 10-year median of 3.68 and 51.6% above the Healthcare Providers & Services industry median of 2.25. Fresenius SE KGaA's overall GF Score™ is 71/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Fresenius SE KGaA (XSWX:FRE), the current Debt-to-EBITDA is 3.41 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fresenius SE KGaA (XSWX:FRE) Overvalued in 2026?
Based on GuruFocus' analysis, Fresenius SE KGaA stock appears to be overvalued.
The current stock price of CHF36.15 is trading 7.9% above its estimated GF Value™ of CHF33.50.
GuruFocus considers Fresenius SE KGaA to be Fairly Valued.
Key valuation signals for XSWX:FRE:
Debt-to-EBITDA: 3.41 (near median its 10-year median of 3.68)
GF Value™: CHF33.50 vs. price of CHF36.15 (7.9% above fair value)
Industry Position: 51.6% above the Healthcare Providers & Services median (#300 of 476)
No single metric tells the full story. See the XSWX:FRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fresenius is a healthcare holding company based in Germany. The company owns a minority stake in dialysis service provider and equipment manufacturer Fresenius Medical Care. The Kabi segment manufactures intravenous drugs, nutrition products, infusion and transfusion therapies, and related pumps. The Helios segment operates private hospitals primarily in Germany and Spain.
71GF Score
Get the complete analysis for XSWX:FRE
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:FRE has been successfully added to your 
